Last reviewed · How we verify
Secukinumab 300 mg
At a glance
| Generic name | Secukinumab 300 mg |
|---|---|
| Also known as | COSENTYX ®, AIN457, AIN457 300 mg |
| Sponsor | GWT-TUD GmbH |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Phase II Interventional Study Evaluating Efficacy and Safety of Secukinumab in Active Severe Takayasu Patients (PHASE2)
- Metformin Combined With Secukinumab for Moderate-to-Severe Plaque Psoriasis in Overweight or Obese Chinese Patients (PHASE4)
- Study of Efficacy and Safety of Secukinumab in Participants With Moderate-severe Rotator Cuff Tendinopathy (PHASE3)
- Study of Efficacy and Safety of Secukinumab in Chinese Adult Patients With Moderate to Severe Hidradenitis Suppurativa (PHASE4)
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
- Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa (PHASE3)
- Open-label, Long-term Safety Study of Secukinumab in Polymyalgia Rheumatica (PMR) (PHASE3)
- Secukinumab Open Label Roll-over Extension Protocol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Secukinumab 300 mg CI brief — competitive landscape report
- Secukinumab 300 mg updates RSS · CI watch RSS
- GWT-TUD GmbH portfolio CI